Awful Jobs Report: ...
Health Care: Drugs
Cell Therapeutics Inc. (CTIC: NASDAQ)
$0.86 -0.03 | -3.86%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 0.87 |
| 52 Week High | 2.24 |
| 52 Week Low | 0.82 |
| Avg. Daily Vol. (Mil) | 1.64 |
| Beta (3 year) | 1.10 |
| Share Related Items | |
| Mkt Cap (Mil) | 196.97 |
| Shares Out (Mil) | 227.71 |
| Float (Mil) | 222.68 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.80 |
| Current Ratio | 2.10 |
| LT Debt/ Equity | 0.27 |
| Total Debt / Equity | 0.31 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 15.18 |
| Price/Cash Flow | -2.30 |
| Per Share Data | |
| Earnings | -0.48 |
| Sales | 0.00 |
| Book Value | 0.06 |
| Cash Flow | -0.37 |
| Business Summary | |
|---|---|
| Cell Therapeutics, Inc. develops, acquires and commercializes novel treatments for cancer. | |
| General Information | |
| 501 Elliott Avenue West
Suite 400 Seattle, WA 98119 |
|
| www.cticseattle.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 95 | |
| CEO: Dr. James A. Bianco,M.D. | |
| Short Interest | |
| Current Month (Mil) | 36.10 |
| Previous Month (Mil) | 28.26 |
| Short Interest Ratio (Days) | 17.20 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -136.10 |
| Return on Investments | -364.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with CTIC
- Portfolio NameUser Type
- ContributorUnder-$10 Setting Up To Tra...
- User2012 stock
- ContributorCancer Drug Stocks to Trade...
- UserImagine!
- Userfrankiesun09@gmail.com
- UserASCO 2010
- Contributor10 Biotech Stocks Facing FD...
- Userbiotech121
- UserJswaim
- UserSLITraders
Latest CTIC Headlines from TheStreet
- Cell Therapeutics Juggles Chainsaws To Distract Investors From Its Dead-End Course 04.19.12 | 03:04 pm
- The 5 Dumbest Things on Wall Street This Week: Feb. 3 02.03.12 | 06:02 am
- The 5 Dumbest Things on Wall Street: Feb. 3
02.03.12 | 05:02 am - Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances 01.30.12 | 05:01 am
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 5 Under-$10 Stocks Set to Soar 12.29.11 | 06:12 pm
- The Worst Biotech CEO of 2011 Is ... 12.09.11 | 07:12 am
- Biotech Stock Mailbag: Affymax 12.02.11 | 06:12 am
- 22 Hot Drugs Facing FDA Approval in 2012 11.29.11 | 08:11 am
- 10 Best Mutual Funds for 2012 11.16.11 | 07:11 am
Press Releases for CTIC
- Cell Therapeutics Completes Acquisition Of Pacritinib A Highly Selective JAK2 Inhibitor - PR Newswire 06.04.12 | 01:06 am
- Cell Therapeutics To Host Investor And Analyst Meeting To Discuss Targeted Agents In Myelofibrosis And High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia On Sunday, June 3, 2012, In Chicago - PR Newswire 06.01.12 | 04:06 pm
- Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published In The Lancet Oncology - PR Newswire 05.31.12 | 01:05 am
- Cell Therapeutics' Aequus BioPharma Validates Its Proprietary GlycoPolymer Technology For The Extension Of The Half-life Of Therapeutic Protein Drugs - PR Newswire 05.30.12 | 01:05 am
- Cell Therapeutics To Host Investor And Analyst Meeting To Discuss Targeted Agents In Myelofibrosis And High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia On Sunday, June 3, 2012, In Chicago - PR Newswire 05.29.12 | 04:05 pm
- Cell Therapeutics Announces Institutional Investor To Purchase $40 Million Of Convertible Preferred Stock And Warrants To Purchase Common Stock - PR Newswire 05.29.12 | 03:05 am
- Cell Therapeutics' Pixuvri® Approved In European Union As Monotherapy To Treat Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas - PR Newswire 05.10.12 | 02:05 pm
- Cell Therapeutics Enters Into Agreement To Acquire Pacritinib, A Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate For Myelofibrosis - PR Newswire 04.19.12 | 01:04 am
- University Of Washington's Neuro-Oncology Program To Investigate Cell Therapeutics' Drug Candidate OPAXIO⢠(Paclitaxel Poliglumex) Plus Radiotherapy For Glioblastoma Multiforme, A Highly Malignant Brain Cancer - PR Newswire 03.27.12 | 01:03 am
- European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri⢠- PR Newswire 02.17.12 | 07:02 am
Partner Headlines for CTIC
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- Cell Therapeutics Plummeting on NDA Withdrawl - Benzinga 01.30.12 | 09:01 am
- US Panel to Review CTIC's Pixantrone - Analyst Blog - Zacks 01.04.12 | 10:01 am
- Mid-Day Update: Stocks Higher; Investors Cheer European Fiscal Deal - NASDAQ 12.09.11 | 05:12 pm
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 11.11.11 | 09:11 am
- CTIC Loss Widens, Resubmits NDA - Analyst Blog - Zacks 10.27.11 | 10:10 am
- 19 Small Cap Stocks Boosted By Institutional Buying - Seeking Alpha 10.11.11 | 08:10 am
- Cell Therapeutics Efforts Validated - Analyst Blog - Zacks 10.07.11 | 04:10 pm
- Morning Market Movers - Benzinga 08.31.11 | 09:08 am
